A multicenter clinical study on transanal endoscopic sphincter-preserving resection of low rectal tumors
-
By
-
Xiaoke Hu
-
Shuaishuai Fan
-
Jia Xue
-
Hongrui Li
-
Guangya Sun
-
Zeyu Cai
-
Wang Le
-
Ruixue Wang
-
Haiqing Hu
-
June 12, 2026
-
Clinical Scorecard: A Multicenter Investigation of Transanal Endoscopic Sphincter-Sparing Resection for Low Rectal Neoplasms
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Transanal Endoscopic Sphincter-Preserving Resection (TA-ESPR) technique for tumor removal. |
| Target Population | |
| Care Setting | |
Key Highlights
- 100% en bloc and complete resection rates achieved.
- 2.7% recurrence rate observed during follow-up.
- No severe adverse events reported.
- 73% of patients had low-grade rectal cancer (source needed).
- Mean follow-up duration of 36.86 months.
Guideline-Based Recommendations
Diagnosis
Management
- TA-ESPR is suggested for patients declining radical surgery (source needed).
Monitoring & Follow-up
Risks
Patient & Prescribing Data
37 patients with low rectal tumors.
Patients opted for TA-ESPR after informed consent, with treatment plans based on histopathological results.
Clinical Best Practices
- Ensure thorough informed consent discussions regarding TA-ESPR (source needed).
- Consider patient’s general condition and tumor characteristics when recommending treatment options (source needed).
- Monitor patients closely postoperatively for recurrence and complications (source needed).
Related Resources & Content
